GAMMA Investing’s Emergent Biosolutions EBS Stock Holding History

GAMMA Investing’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.08K	Sell	619 -1	-0.2%	-$7	﹤0.01%	3736
2026 Q2	$5.2K	Buy	620 +197	+47%	+$1.65K	﹤0.01%	3449
2026 Q1	$3.51K	Buy	423 +64	+18%	+$663	﹤0.01%	3498
2025 Q4	$4.44K	Buy	359 +72	+25%	+$771	﹤0.01%	3335
2025 Q3	$2.53K	Sell	287 -109	-28%	-$848	﹤0.01%	3389
2025 Q2	$2.53K	Sell	396 -190	-32%	-$1.09K	﹤0.01%	3338
2025 Q1	$2.85K	Sell	586 -1,028	-64%	-$8.51K	﹤0.01%	3298
2024 Q4	$15.4K	Sell	1,614 -96	-6%	-$881	﹤0.01%	2397
2024 Q3	$14.3K	Buy	1,710 +968	+130%	+$8.8K	﹤0.01%	2295
2024 Q2	$5.06K	Buy	+742	New	+$3.19K	﹤0.01%	2573

Other funds holding EBS

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

TCM

Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

CIM

Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return

GAMMA Investing's EBS Position: Q3 2026 in Review

GAMMA Investing reduced its Emergent Biosolutions (EBS) stake by 0.16% in Q3 2026, selling an estimated $7 and leaving 619 shares worth $4.08K. The position accounts for ﹤0.01% of the portfolio, ranked #3736.

GAMMA Investing first reported a position in EBS in Q2 2024 and has held it in 10 quarters since. The position peaked at $15.4K in Q4 2024. 9 funds tracked by Wall St. Rank hold EBS as of Q3 2026.

GAMMA Investing held 619 shares of Emergent Biosolutions worth $4.08K as of Q3 2026.
GAMMA Investing sold 1 Emergent Biosolutions share in Q3 2026, an estimated $7.
Emergent Biosolutions made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3736 holding.
GAMMA Investing first reported a position in Emergent Biosolutions in Q2 2024 and has held it in 10 quarters since.
GAMMA Investing's Emergent Biosolutions position peaked at $15.4K in Q4 2024.
9 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.